These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7853924)

  • 1. [How the EEC membership influences drug supply in Sweden].
    Lennholm B
    Lakartidningen; 1995 Feb; 92(6):491-3. PubMed ID: 7853924
    [No Abstract]   [Full Text] [Related]  

  • 2. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 3. Gray marketing of pharmaceuticals.
    Chaudhry PE; Walsh MG
    J Health Care Mark; 1995; 15(3):18-22. PubMed ID: 10172516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 5. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 6. [The structure of distribution of pharmaceutical products in the countries of the EEC].
    Passerini F
    Boll Chim Farm; 1990 May; 129(5):199-209. PubMed ID: 2083056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceuticals gray markets turn off-white.
    Lowe LS; McCrohan KF
    J Hosp Mark; 1989; 3(2):121-31. PubMed ID: 10318329
    [No Abstract]   [Full Text] [Related]  

  • 8. Europe fiddles while innovation burns.
    Frantz S
    Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 10. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug control within the EEC I: coordination during the 1990's].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(3):100-1. PubMed ID: 1734132
    [No Abstract]   [Full Text] [Related]  

  • 12. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 13. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 14. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 15. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals. Adopt an orphan.
    Karr A
    Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
    [No Abstract]   [Full Text] [Related]  

  • 17. The expectations of the European Allergen Manufacturers Group concerning the EEC directives for allergen extracts.
    Williams GD
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1992; (85):7-17. PubMed ID: 1540299
    [No Abstract]   [Full Text] [Related]  

  • 18. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugmakers' price plan ruled to be price-fixing by agency.
    Burda D
    Mod Healthc; 1993 Oct; 23(41):8. PubMed ID: 10129330
    [No Abstract]   [Full Text] [Related]  

  • 20. Excellence in education and training advances competitiveness of the pharmaceutical industry in Europe.
    Bjerrum OJ
    Eur J Pharm Sci; 2011 Sep; 44(1-2):174-5. PubMed ID: 21782938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.